Carolyn Hoppe

Pfizer (United States) — United States

Medicine · Health Sciences

36h-index4.1kcitations111works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hemoglobinopathies and Related Disorders(99), Iron Metabolism and Disorders(58), Blood groups and transfusion(30), Folate and B Vitamins Research(18), Myeloproliferative Neoplasms: Diagnosis and Treatment(12)

Publications111 total

PB2516: ACTIGRAPHY IMPROVEMENT WITH VOXELOTOR (ACTIVE) STUDY: IMPACT OF VOXELOTOR ON PHYSICAL ACTIVITY, FATIGUE, AND SLEEP QUALITY
HemaSphere·2023Open Access
A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease
European Journal of Clinical Pharmacology·2023· 11 citedOpen Access
Active Study: Impact of Voxelotor on Sleep Quality, Physical Activity, and Patient-Reported Outcomes
Blood·2022· 1 cited
Insights into Vaso-Occlusive Crises-Related Readmissions in Patients with SCD across Geographic Regions
Blood·2022· 3 cited
P-059: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 RESOLVE TRIAL INVESTIGATING THE EFFICACY OF VOXELOTOR WITH STANDARD OF CARE IN THE RESOLUTION OF LEG ULCERS IN PATIENTS WITH SICKLE CELL DISEASE
HemaSphere·2022Open Access
Adjuvant low‐dose ketamine for paediatric and young adult sickle cell vaso‐occlusive episodes in the emergency department
British Journal of Haematology·2022· 1 cited
Successful Implementation of Newborn Screening for Hemoglobin Disorders in the Philippines
International Journal of Neonatal Screening·2021· 14 citedOpen Access
Adjuvant low-dose ketamine for pediatric sickle cell vaso-occlusive episodes in the emergency department
2020Open Access
Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial
Blood·2020· 3 cited
Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study
Journal of Clinical Medicine·2019· 14 citedOpen Access
Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study
Blood·2019· 4 cited
Chronic Kidney Disease Is Under-Screened in SCD and Mild Albuminuria Is Associated with a Drop in Hemoglobin: A Report from the Grndad Sickle Cell Registry
Blood·2019
Sickle cell disease: current treatment and emerging therapies.
PubMed·2019· 42 cited
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
New England Journal of Medicine·2019· 582 citedOpen Access
S147 RESULTS FROM THE RANDOMIZED PLACEBO‐CONTROLLED PHASE 3 HOPE TRIAL OF VOXELOTOR IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE
HemaSphere·2019Open Access
Sickle Cell Disease
Hematology/Oncology Clinics of North America·2019· 37 cited
Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease
Blood·2018· 5 cited
Iron Overload Is Under-Recognized and Under-Treated in SCD: A Report from the Grndad Registry
Blood·2018
Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease
Blood·2018· 4 cited
Newborn Screening for SCD in the USA and Canada
International Journal of Neonatal Screening·2018· 44 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Elliott Vichinsky(13), Lori Styles(13), Matthew M. Heeney(7), William Klitz(6), Patricia Brown(6), Lori E. Heath(6), Joseph A. Jakubowski(6), Julie Kanter(5), Chunmei Zhou(5), Hoda Hassab(4), Carlton Dampier(4), David C. Rees(4), Victor R. Gordeuk(3), Miguel R. Abboud(3), Samir K. Ballas(3), Marilyn J. Telen(3), Suzanne Cheng(3), Bertram H. Lubin(3), Baba Inusa(3), Raffaella Colombatti(3)